Association of HLA Polymorphisms with Post-transplant Lymphoproliferative Disorder in Solid-Organ Transplant Recipients
Ran Reshef(Abramson Cancer Center), De.E. Tsai(University of Pennsylvania), Edward A. Stadtmauer(University of Pennsylvania), Malek Kamoun(Hospital of the University of Pennsylvania), Marlise R. Luskin(Dana-Farber Cancer Institute), David Porter(University of Pennsylvania), J E Tomaszewski(University of Pennsylvania), Saran Vardhanabhuti, Daniel F. Heitjan(Southern Methodist University)
Cited by 56
Related Papers
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
|Journal of Clinical Oncology|2019|441